Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data
Tonix Pharmaceuticals presented preclinical data on TNX-801, a single-dose mpox vaccine that demonstrates robust protection across animal models, potentially offering a significant breakthrough in combating global mpox outbreaks.
Tonix Pharmaceuticals has unveiled promising preclinical results for its single-dose mpox vaccine candidate TNX-801 at the World Vaccine Congress Washington 2025. The oral presentation highlighted the vaccine's potential to provide comprehensive protection against mpox and rabbitpox, with efficacy demonstrated across various animal subjects, including those with compromised immune systems.
The minimally replicative live-virus vaccine showed durable protection lasting six months, aligning closely with the World Health Organization's preferred vaccine target profile. This development is particularly significant given the recent global health emergencies involving mpox outbreaks.
TNX-801's ability to protect immunocompromised subjects represents a critical advancement in vaccine technology. The six-month duration of protection suggests potential for long-term immune response, which could be crucial in managing future infectious disease challenges.
By presenting a single-dose vaccine that demonstrates broad protective capabilities, Tonix Pharmaceuticals is positioning itself at the forefront of innovative infectious disease prevention strategies. The research suggests potential applications not only for current mpox outbreaks but also for preparing against future emerging viral threats.